Skip to main content
KISQALI patient portrayal.

KISQALI—straightforward assessments and less monitoring over time

Complete most of the scheduled assessments for KISQALI within the first 2 months of therapy—with none beyond Cycle 6

Plan ahead—work with your patients to schedule these assessments as soon as possible to help them start and stay on therapy

Table describing the frequency of scheduled assessments for KISQALI within the first 6 months of therapy. CBC and LFT: baseline, day 14 of cycle 1, day 1 and day 14 of cycle 2, and day 1 of cycles 3-6. Electrolytes: baseline, day 1 of cycle 2, and day 1 of cycles 3-6. ECG: baseline and day 14 of cycle 1.

Monitoring requirements based on a 28-day treatment cycle. 
Additional monitoring may be required as clinically indicated.

Routine monitoring for lab abnormalities1
  • Blood tests are performed at baseline, on Day 14 of Cycle 1, on Days 1 and 14 of Cycle 2, on Day 1 of Cycles 3 through 6, and as clinically indicated

  • For LFTs, if grade ≥2 abnormalities are noted, more frequent monitoring is recommended

  • Correct any electrolyte abnormalities prior to treatment

2 required ECG assessments completed within the first 2 weeks of treatment1 
  • ECGs are performed at baseline, on Day 14 of Cycle 1, and as clinically indicated

  • KISQALI should only be initiated in patients with QTcF <450 ms

  • In case of QTcF prolongation during therapy, more frequent assessments are recommended

The majority of adverse reactions with KISQALI were manageable and reversible

Review the dose adjustment guidance and safety information for KISQALI

In NATALEE, incidence of QT prolongation observed with KISQALI was low

Graphic showing the incidence of QT prolongation in the NATALEE trial, with 4.3% for all grades and 0.3% for grades ≥3. Most cases of QT prolongation were moderate and reversible, and the majority occurred within the first four weeks of treatment.

Among cases of QT prolongation1

  • 0.3% had a >500 ms postbaseline QTcF value

  • 2% had a >60 ms increase from baseline in QTcF interval

  • There were no reported cases of torsades de pointes

ECG device monitoring program

A flexible program designed to meet the needs of you and your patients’ treatment plans. 

The KISQALI ECG Device Monitoring Program can provide you or your patients with a KardiaMobile 6L ECG device so ECG assessments can be completed in seconds in your office or at home.

  • In-Office option for eligible practices to receive a fast and simple-to-use ECG monitoring device that will allow them to easily monitor their patients taking or being evaluated for KISQALI

  • Direct-to-Patient option designed so patients can complete their ECG without a trip to the office

  • There is no direct cost to you or your patients for participating in this program

  • Actual ECG reading takes seconds and fits into any office workflow. QTcF results from the ECG device are available instantaneously, with the option for a board-certified cardiologist overread

Limitations apply. KISQALI ECG Device Monitoring Program is only permitted to be used for monitoring or evaluating a patient for the current or potential administration of ribociclib. The equipment or services are not permitted to be used for any purpose outside of the scope of the program. You must not bill any entity or person for any equipment or services relating to the provision or interpretation of the ECG. In the event that you fail to abide by the rules of the KISQALI ECG Device Monitoring Program, your participation in the program may be terminated or modified at any time without prior notice, and you may be subject to additional remedies. Additional terms and conditions apply.

Sunshine Act costs may apply.

For additional information, please contact your Novartis Oncology Specialist.

Learn more about the AliveCor® KardiaMobile 6L ECG device and how to use it

In-Office ECG monitoring with AliveCor® KardiaMobile 6L 

resource thumbnail

KISQALI Starter Guide

This guide provides assessment, dosing, and access and support information to help you get your patients started and maintain treatment with KISQALI.
Download
resource thumbnail

KISQALI Assessments Checklist

Plan ahead with this checklist to help your patients start and stay on therapy with KISQALI.
Download
resource thumbnail

KISQALI Treatment Guide

A comprehensive guide to treatment with KISQALI, with dedicated sections to support you in treating your patients with HR+/HER2- early or metastatic breast cancer.
Download
resource thumbnail

KISQALI ECG Program Brochure

The KISQALI ECG Device Program is a flexible program designed to meet the needs of you and your patients' treatment plan. Learn how your patients can receive their ECG assessment in seconds in your office or home.
Download
resource thumbnail

KISQALI Financial Assistance Slim Jim

Information about financial support for KISQALI
Download
CBC=complete blood count; ECG=electrocardiogram; LFT=liver function test; QTcF=QT interval corrected by Fridericia’s formula.
 
References: 1. Kisqali. Prescribing information. Novartis Pharmaceuticals Corp. 2. Hortobagyi GN, Stroyakovskiy D, Yardley DA, et al. Ribociclib + nonsteroidal aromatase inhibitor as adjuvant treatment in patients with HR+/HER2- early breast cancer: final invasive disease-free survival analysis from the NATALEE trial. Presented at: San Antonio Breast Cancer Symposium; December 5-9, 2023; San Antonio, TX.